WillItSurvive
Pharma and healthcare groups · subsidiary of China Resources Pharmaceutical Group Limited · China

Tasly Pharmaceutical Group

Tianjin maker of Danshen Dropping Pills, now controlled by China Resources Pharmaceutical.

Protection under test
Assessed 25 July 2026 · Evidence as of 25 July 2026
Something worth protecting exists and is being tested right now.
On the recordSince 25 July 2026 · Checkable from August 2026 · Every call on the record Checkpoint: Q2 2026 earnings and signs of China Resources' capital-allocation plan for Tasly
The call

Tasly's old-line TCM approvals still protect it from copycats and AI, but its new state-backed owner, not a competitor, will decide whether it grows or gets quietly folded in.

Tasly makes traditional Chinese medicine and pharmaceutical products and has been doing so profitably for 30 years with government approval and its own supply chain. It is hard to copy because it has regulatory licenses, decades of manufacturing know-how, and supplier relationships, and artificial intelligence cannot replace the actual factory work or distribution network. However, the company was acquired by a state-owned parent company in March 2025, the Chinese government is pushing down drug prices through new insurance rules, and pharmacy sales dropped 14 percent in the last year, so what matters most is whether the new owner will invest in growth or just cut costs and shrink the business.

Why
01
AI pressure: None apparent. Tasly uses its own AI4TCM platform to speed drug research; no AI product replaces regulated TCM manufacturing or approvals. Could AI do the core job? Unlikely.
02
Bigger players: China Resources Pharmaceutical Group (via CR Sanjiu). CR Sanjiu completed a 28% controlling buy-in in March 2025; the risk now is how CR runs Tasly, not a rival stealing its customers. Could a giant copy it? Probably.
03
What protects it. NMPA approval since 1993, proprietary Danshen formula, and distribution into about 26 countries keep rivals from copying its core product.
What would change this call
China Resources Pharmaceutical announces asset injections or cross-selling of Tasly into its hospital network by Q2 2026. Would show CR is investing for growth rather than harvesting the acquired unit.
Tasly reports two consecutive quarters of revenue growth after FY2025 decline. Would indicate the procurement/margin pressure and integration disruption are stabilizing.
Further headcount cuts beyond the 3.6% FY2025 reduction disclosed in 2026 filings. Would suggest CR is treating Tasly as a cost-cutting integration target rather than a growth flagship.
Key numbers
  • FY2025 revenue RMB 8.236bn, down 3.08% YoY (2025-12-31)
  • Chain-pharmacy revenue fell 14.24% in FY2025 (2025-12-31)
  • CR Sanjiu paid RMB 6.2bn for 28% stake (2024-08-04)
Named risks
  • China's centralized drug procurement (VBP) and outpatient insurance reforms compressing margins. Severity: high
  • Chain-pharmacy revenue fell 14.24% in FY2025, dragging total revenue down 3.08%. Severity: high
  • Post-merger integration uncertainty as founder lost control to China Resources Sanjiu in March 2025. Severity: medium
  • Headcount reduction of 3.6% in 2025 signals possible cost-cutting under new state-linked parent. Severity: medium
Rivals, as read in July 2026
RivalDirectionEvidence
China Resources Sanjiu / China Resources Pharmaceutical GroupcontestingBecame 28% controlling shareholder March 27, 2025, converting former rival into parent overseeing integration
Yunnan Baiyaogaining onRanked as most valuable TCM raw-material company by market cap as of 2022 statistics
Tong Ren Tanggaining onRanked China's strongest pharma brand by Brand Finance in both 2024 and 2026 rankings
Guangzhou Pharmaceutical (Baiyunshan)gaining onNamed fastest-growing Chinese pharma brand and top-ranked TCM brand by value in April 2026 Brand Finance report
Questions people ask
Is Tasly Pharmaceutical profitable in 2025?
Yes. Tasly reported net profit of approximately RMB 1.10 billion for FY2025 despite total revenue falling 3.08% YoY to RMB 8.236 billion as of December 31, 2025, per its filing dated February 6, 2026.
Who owns Tasly Pharmaceutical now?
China Resources Sanjiu completed acquisition of a 28% stake for roughly RMB 6.2 billion on March 27, 2025, making it Tasly's controlling shareholder via parent China Resources Pharmaceutical Group. Founder Yan Xijun and family retained over 17% but lost control.
Could AI replace Tasly's drug manufacturing business?
Unlikely. Tasly holds NMPA regulatory approval since 1993 for its flagship Danshen Dropping Pills and proprietary herb supply chains that AI cannot replicate. It uses AI internally as an R&D tool, publishing its own AI4TCM platform in November 2025.
Is Tasly Pharmaceutical laying off employees?
Modestly. Headcount fell to 10,563 employees as of December 31, 2025, a decrease of 395 workers (-3.6%) from the prior year, coinciding with post-acquisition integration under new parent China Resources Sanjiu.
Who is Tasly Pharmaceutical's biggest competitor?
Domestically, Yunnan Baiyao and Tong Ren Tang rank as stronger TCM brands per Brand Finance's 2026 ranking, and Guangzhou Pharmaceutical was named the fastest-growing Chinese pharma brand in 2026. Its new majority owner, China Resources Sanjiu, was formerly a rival.
What is Tasly Pharmaceutical's flagship product?
Compound Danshen Dropping Pills, NMPA-approved in China since 1993 and marketed abroad as Dantonic/T89 in about 26 countries outside the US. As of 2023, US Phase III trials for angina (NCT03789552) and altitude sickness (NCT04993729) were still active.
Timeline
  • 2026-03-19FY2025 annual report filing proposes RMB 1-per-10-shares dividend, discloses integration progress
  • 2026-02-06FY2025 results: revenue RMB 8.236bn, down 3.08% YoY, chain-pharmacy income down 14.24%
  • 2025-11-17Tasly subsidiary publishes SZBC-AI4TCM AI research platform citing DeepSeek-V3
  • 2025-09-15Tasly makes early-stage VC investment in Rui Therapeutics
  • 2025-03-27China Resources Sanjiu completes 28% stake acquisition, becomes controlling shareholder
  • 2024-08-04China Resources Sanjiu agrees to acquire 28% of Tasly for ~RMB 6.2bn (~USD 869m)
  • 1993Compound Danshen Dropping Pills approved by Chinese regulator (NMPA predecessor)
Revision history
25 July 2026
First assessed. Protection under test. The text above is fixed as of this date and is not edited afterwards.
In the same band
SolventumNovo NordiskBaxter International
More in Pharma and healthcare groups →
Sources